Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Incidence of Invasive Fungal Infections in Acute Leukemia Patients Utilizing Micafungin Prophylaxis Compared to Second-Generation Azole Prophylaxis

Heather Morris, PharmD, BCPS, Meredith T. Moorman, PharmD, BCOP, CPP, Melissa C. Mackey, PharmD, BCPS, BCOP, Harry P. Erba, MD PhD, Thomas W. LeBlanc, MDMA,MHS, David A. Rizzieri, MD, Ian Barak, MS, Zhiguo Li, PhD, Tanya Zapolskaya, PharmD, BCPS, BCOP

Blood (2019) 134 (Supplement_1): 5105.

https://doi.org/10.1182/blood-2019-132197

Published: 2019

Journal Articles

Single Centre Experience in Treating Elderly Patients with Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndrome with a Combination of Low Dose Cytarabine, Venetoclax and Fluconazole (VeLDAC-F)

Lauren Child, Henry Chan, MBChB, Ross Alistair Henderson, PhD MBChB, Anna Elinder, MBChB, Eileen Merriman, MBChB, Merit Hanna, MBChB, David Simpson, MBChB, FRACP, FRCPA

Blood (2018) 132 (Supplement 1): 5220.

https://doi.org/10.1182/blood-2018-99-115993

Published: 2018

Journal Articles

Venetoclax with Low-Dose Cytarabine Induces Rapid, Deep, and Durable Responses in Previously Untreated Older Adults with AML Ineligible for Intensive Chemotherapy

Andrew Wei, MD, Stephen A. Strickland, MD, Jing-Zhou Hou, MD PhD, Walter Fiedler, MD, Tara L Lin, MD, Roland B. Walter, MDPhDMS, Anoop K Enjeti, MBBS,FRCPA,MDMRCP, Wan-Jen Hong, Brenda Chyla, Relja Popovic, PhD, Kaffa Fakouhi, Tu Xu, PhD, John Hayslip, Gail J. Roboz, MD

Blood (2018) 132 (Supplement 1): 284.

https://doi.org/10.1182/blood-2018-99-118729

Published: 2018

Journal Articles

Results of Off-Label Venetoclax Use in Combination with Low-Intensity Chemotherapy in Patients with Relapsed and Refractory Myeloid Malignancies

Caitlin R Rausch, PharmD, Courtney D. DiNardo, MDMSc, Tapan Kadia, MD, Koichi Takahashi, MD, Nitin Jain, MD, Christopher B Benton, MD, Philip A Thompson, MBBS, Maro Ohanian, DO, Wendy Covert, PharmD, Morgan Mace, PharmD, Kayleigh Marx, PharmD, Naveen Pemmaraju, MD, Naval Daver, MD, Elias J. Jabbour, MD, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MBBS, Marina Konopleva, MD PhD, Hagop M. Kantarjian, MD

Blood (2017) 130 (Supplement 1): 1356.

https://doi.org/10.1182/blood.V130.Suppl_1.1356.1356

Published: 2017

Journal Articles

Repurposing Itraconazole As an Anti-Cancer Agent Against Diffuse Large B-Cell Lymphoma

Juan Gu, MD PhD, Lianjuan Yang, MD PhD, Cory Mavis, BSc, MSc, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2017) 130 (Supplement 1): 5195.

https://doi.org/10.1182/blood.V130.Suppl_1.5195.5195

Published: 2017

Journal Articles

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML

Steven Knapper, Nigel Russell, Amanda Gilkes, Robert K. Hills, Rosemary E. Gale, James D. Cavenagh, Gail Jones, Lars Kjeldsen, Michael R. Grunwald, Ian Thomas, Heiko Konig, Mark J. Levis, Alan K. Burnett

Blood (2017) 129 (9): 1143–1154.

https://doi.org/10.1182/blood-2016-07-730648

Published: 2017

Includes: Supplemental data

Journal Articles

Anti-Fungal Prophylaxis Using Intermediate Dose Ambisome Is Associated with Delayed Methotrexate Clearance in Pediatric Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Liora M. Schultz, MD, Karan Kumar, MD, Suzette Stone, Elizabeth Callard, Jessica Witkowski, MD, Leigh Shinn, Lisa Pinner, Shizuka Franklin, Julianna Kula, Namrata Patel, Prianka Kumar, Kenneth I. Weinberg, MD, Matthew Porteus, MD PhD, Rajni Agarwal, MD, Ami Shah, MD, Sandhya Kharbanda, MD

Blood (2016) 128 (22): 5762.

https://doi.org/10.1182/blood.V128.22.5762.5762

Published: 2016

Journal Articles

Treatment Patterns and Outcomes Among Patients with Higher-Risk Myelodysplastic Syndromes Treated in a Real-World Setting: Electronic Medical Record-Based Data

Jill A Bell, PhD, Aaron Galaznik, MD, Eileen Farrelly, MPH, Marlo Blazer, PharmD, BCOP, Brian Seal, RPh, MBA, PhD, Huai-Che Shih, PhD, Augustina Ogbonnaya, MPH, Michael Eaddy, PharmD, PhD, Bruce J Dezube, MD

Blood (2016) 128 (22): 5540.

https://doi.org/10.1182/blood.V128.22.5540.5540

Published: 2016

Journal Articles

A Double-Blind, Multicentre, Randomised, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of Prophylactic Liposomal Amphotericin B (AmBisome®) for the Prevention of Invasive Fungal Infections in Subjects Receiving Remission-Induction Chemotherapy for Acute Lymphoblastic Leukaemia (AmBiGuard trial)

Oliver Cornely, MD, Thibaut Leguay, MD, Johan Maertens, MD, Carlo Castagnola, MD, Achilles Anagnostopoulos, Bernadino Allione, MD, Claus Peter Heussel, MD, J Peter Donnelly, PhD, Samir G. Agrawal, Will Garner, Catherine Simcock, Michael J. Hawkins, MD, Nicola Goekbuget, MD

Blood (2014) 124 (21): 3646.

https://doi.org/10.1182/blood.V124.21.3646.3646

Published: 2014

Journal Articles

A Randomised Comparison of the Sequential Addition of the FLT3 Inhibitor Lestaurtinib (CEP701) to Standard First Line Chemotherapy for FLT3-Mutated Acute Myeloid Leukemia: The UK Experience

Steven Knapper, DM, Robert K Hills, MA MSc DPhil, James D Cavenagh, MD, Lars Kjeldsen, MDPhD, Ann E. Hunter, MBBS, Richard E Clark, MBBS MD, Michael Dennis, MD, Donald Milligan, MD, Mark J Levis, MDPhD, Nigel Russell, Alan K. Burnett, MD

Blood (2014) 124 (21): 3736.

https://doi.org/10.1182/blood.V124.21.3736.3736

Published: 2014

Journal Articles

Hepatic and Metabolic Complications In Adult Patients With Acute Lymphoblastic Leukemia (ALL) Treated With Asparaginase-Containing Combination Chemotherapy: A Single Center Experience

Jason N. Barreto, PharmD, Kristen B. McCullough, PharmD, Candy S Peskey, PharmD, Louis Letendre, MD, William Hogan, MD, Aref Al-Kali, MD, Mark R. Litzow, MD, Mrinal M. Patnaik, MBBS

Blood (2013) 122 (21): 1405.

https://doi.org/10.1182/blood.V122.21.1405.1405

Published: 2013

Journal Articles

Lestaurtinib FLT3 Inhibitory Activity Is Modulated by Concomitant Azole Therapy and May Influence Relapse Risk.

Steven Knapper, Alan K. Burnett, Robert K Hills, Donald Small, Mark Levis

Blood (2009) 114 (22): 789.

https://doi.org/10.1182/blood.V114.22.789.789

Published: 2009

Journal Articles

Pretransplant Factors That Influence Intravenous Busulfan Kinetics in Adult Patients.

Ali McBride, PharmD, Karen Fancher, PharmD, Jongphil Kim, PhD, Donn Davis, PharmD, Michelle Conwell, PharmD, Teresa Field, MD, PhD, Claudio Anasetti, MD, Janelle Perkins, PharmD

Blood (2009) 114 (22): 3350.

https://doi.org/10.1182/blood.V114.22.3350.3350

Published: 2009

Journal Articles

Phase I Trial of Vorinostat (SAHA) in Combination with Alvocidib (Flavopiridol) in Patients with Relapsed, Refractory or (Selected) Poor Prognosis Acute Leukemia or Refractory Anemia with Excess Blasts-2 (RAEB-2)

Steven Grant, MD, Sarah Kolla, Leonardo Andres Sirulnik, MD, PhD, Geoffrey Shapiro, Jeffrey Supko, Brenda Cooper, Edward Perkins, Viswanathan Ramakrishnan, Igor Espinoza-Delgado, MD, M B Tombes, John D Roberts

Blood (2008) 112 (11): 2986.

https://doi.org/10.1182/blood.V112.11.2986.2986

Published: 2008

Journal Articles

Primary Prophylaxis against Invasive Fungal Infections (IFI) with Posaconazole (POS) or Voriconazole (VRC) Shows Better Efficacy Compared to No Systemic Prophylaxis during Induction and Consolidation Chemotherapy Cycles of Adult Acute Leukemia Patients

Mario E Ojeda Uribe, MD, Catherine Berg, Alain Gravet, Eric Sauleau, Dominique Bourderont, Celine Haby

Blood (2008) 112 (11): 4834.

https://doi.org/10.1182/blood.V112.11.4834.4834

Published: 2008

Journal Articles

Phase I Trial of Sphingosomal Vincristine (SV, Marqibo®) and Dexamethasone in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL).

Deborah A. Thomas, MD, Hagop M. Kantarjian, MD, Leonard Heffner, MD, Wendy Stock, MD, Guillermo Garcia-Manero, MD, Stefan Faderl, MD, Alessandra Ferrajoli, MD, Francis Giles, MD, William Wierda, MD, Farhad Ravandi-Kashani, MD, Gavin Choy, PharmD, Gregory I. Berk, MD, Susan O’Brien, MD

Blood (2006) 108 (11): 4539.

https://doi.org/10.1182/blood.V108.11.4539.4539

Published: 2006

Journal Articles

Preliminary Results of Phase I Trial of Sphingosomal Vincristine (SV) and Dexamethasone in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL).

Deborah A. Thomas, MD, Guillermo Garcia-Maneron, MD, Stefan Faderl, MD, Susan O’Brien, MD, Francis J. Giles, MD, Alessandra Ferrajoli, MD, William Wierda, MD, PhD, Srdan Verstovsek, MD, PhD, Jorge Cortes, MD, Hagop Kantarjian, MD

Blood (2004) 104 (11): 2735.

https://doi.org/10.1182/blood.V104.11.2735.2735

Published: 2004

Journal Articles

Antifungal Prophylaxis with Itraconazole in Patients with Acute Leukemia and after Stem Cell Transplantation (SZT): High Plasma Concentrations with a Loading Dose Strategy.

Michael Sandherr, MD, Michael Vogeser, MD, Carsten Hartig, MD, Christoph Aulmann, MD, Stefanie Fuhrmann, MD, Linda Wondzinski, MD, Daniel Oruzio, MD, Guenter Schlimok, MD

Blood (2004) 104 (11): 5062.

https://doi.org/10.1182/blood.V104.11.5062.5062

Published: 2004

Journal Articles

Cyclophosphamide metabolism is affected by azole antifungals

Kieren A. Marr, Wendy Leisenring, Fulvio Crippa, John T. Slattery, Lawrence Corey, Michael Boeckh, George B. McDonald

Blood (2004) 103 (4): 1557–1559.

https://doi.org/10.1182/blood-2003-07-2512

Published: 2004

NARROW

Incidence of Invasive Fungal Infections in Acute Leukemia Patients Utilizing Micafungin Prophylaxis Compared to Second-Generation Azole Prophylaxis

Single Centre Experience in Treating Elderly Patients with Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndrome with a Combination of Low Dose Cytarabine, Venetoclax and Fluconazole (VeLDAC-F)

Venetoclax with Low-Dose Cytarabine Induces Rapid, Deep, and Durable Responses in Previously Untreated Older Adults with AML Ineligible for Intensive Chemotherapy

Results of Off-Label Venetoclax Use in Combination with Low-Intensity Chemotherapy in Patients with Relapsed and Refractory Myeloid Malignancies

Repurposing Itraconazole As an Anti-Cancer Agent Against Diffuse Large B-Cell Lymphoma

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML

Anti-Fungal Prophylaxis Using Intermediate Dose Ambisome Is Associated with Delayed Methotrexate Clearance in Pediatric Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Treatment Patterns and Outcomes Among Patients with Higher-Risk Myelodysplastic Syndromes Treated in a Real-World Setting: Electronic Medical Record-Based Data

A Randomised Comparison of the Sequential Addition of the FLT3 Inhibitor Lestaurtinib (CEP701) to Standard First Line Chemotherapy for FLT3-Mutated Acute Myeloid Leukemia: The UK Experience

Hepatic and Metabolic Complications In Adult Patients With Acute Lymphoblastic Leukemia (ALL) Treated With Asparaginase-Containing Combination Chemotherapy: A Single Center Experience

Lestaurtinib FLT3 Inhibitory Activity Is Modulated by Concomitant Azole Therapy and May Influence Relapse Risk.

Pretransplant Factors That Influence Intravenous Busulfan Kinetics in Adult Patients.

Phase I Trial of Vorinostat (SAHA) in Combination with Alvocidib (Flavopiridol) in Patients with Relapsed, Refractory or (Selected) Poor Prognosis Acute Leukemia or Refractory Anemia with Excess Blasts-2 (RAEB-2)

Primary Prophylaxis against Invasive Fungal Infections (IFI) with Posaconazole (POS) or Voriconazole (VRC) Shows Better Efficacy Compared to No Systemic Prophylaxis during Induction and Consolidation Chemotherapy Cycles of Adult Acute Leukemia Patients

Phase I Trial of Sphingosomal Vincristine (SV, Marqibo®) and Dexamethasone in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL).

Preliminary Results of Phase I Trial of Sphingosomal Vincristine (SV) and Dexamethasone in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL).

Antifungal Prophylaxis with Itraconazole in Patients with Acute Leukemia and after Stem Cell Transplantation (SZT): High Plasma Concentrations with a Loading Dose Strategy.

Cyclophosphamide metabolism is affected by azole antifungals

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only